McKesson Corporation $MCK Shares Sold by Legacy Financial Independent Advisors LLC

Legacy Financial Independent Advisors LLC cut its holdings in shares of McKesson Corporation (NYSE:MCK) by 81.3% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 636 shares of the company’s stock after selling 2,764 shares during the quarter. Legacy Financial Independent Advisors LLC’s holdings in McKesson were worth $543,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in MCK. Nvwm LLC raised its position in McKesson by 933.3% in the 3rd quarter. Nvwm LLC now owns 31 shares of the company’s stock worth $26,000 after purchasing an additional 28 shares during the period. Delos Wealth Advisors LLC bought a new stake in McKesson in the second quarter worth $27,000. Trellis Wealth Advisors LLC purchased a new stake in McKesson during the third quarter valued at about $32,000. Clearstead Trust LLC purchased a new stake in McKesson during the second quarter valued at about $37,000. Finally, GK Wealth Management LLC bought a new position in shares of McKesson during the third quarter valued at about $38,000. 85.07% of the stock is currently owned by institutional investors.

McKesson News Summary

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: For fiscal Q2 2027, McKesson reported adjusted EPS of $11.68 versus analyst estimates near $10.70, while revenue of about $111 billion also topped expectations and grew roughly 7.5% year over year. MCK Q2 Earnings Beat Estimates on Specialty Growth, Outlook Raised
• Positive Sentiment: Management raised fiscal 2027 adjusted EPS guidance to $45.60–$46.40, citing specialty-drug demand, higher prescription volumes, operating improvements and GLP-1 momentum. The company also completed its $2.25 billion Precision Medicine Group acquisition, expanding its healthcare services footprint. Earnings Call Highlights: Raised Guidance, GLP-1 Momentum
• Positive Sentiment: Several firms raised targets, including TD Cowen, Leerink Partners and Evercore ISI to $1,200; Deutsche Bank raised its target to $1,120. RBC also praised McKesson’s execution, and a Seeking Alpha analysis described normalized earnings as supporting an attractive valuation. TD Cowen Raises Price Target
• Neutral Sentiment: EVP Francisco Fraga sold 600 shares under a pre-arranged trading plan to cover tax withholding on vested equity awards; he retained 5,064 shares, making the transaction less indicative of a change in business outlook. SEC Filing
• Negative Sentiment: RBC’s “sector perform” rating came with a $965 target—below the recent share price—suggesting limited upside in that firm’s view despite its target increase. RBC on McKesson’s Execution

Insider Transactions at McKesson

In other news, EVP Francisco Fraga sold 600 shares of the business’s stock in a transaction that occurred on Wednesday, November 4th. The stock was sold at an average price of $1,050.00, for a total transaction of $630,000.00. Following the transaction, the executive vice president directly owned 5,064 shares of the company’s stock, valued at approximately $5,317,200. The trade was a 10.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Bradley Lerman sold 301 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $892.33, for a total value of $268,591.33. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 1,812 shares of company stock worth $1,794,182. 0.06% of the stock is currently owned by insiders.

McKesson Trading Up 0.6%

Shares of NYSE:MCK opened at $1,075.38 on Friday. The company has a 50-day moving average price of $934.72 and a 200-day moving average price of $866.92. The company has a market cap of $125.38 billion, a price-to-earnings ratio of 27.65, a price-to-earnings-growth ratio of 2.13 and a beta of 0.27. McKesson Corporation has a 12 month low of $723.68 and a 12 month high of $1,121.50.

McKesson (NYSE:MCK) last announced its quarterly earnings results on Wednesday, November 4th. The company reported $11.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.72 by $0.96. McKesson had a negative return on equity of 235.48% and a net margin of 1.12%. The company had revenue of $110.96 billion for the quarter, compared to the consensus estimate of $109.90 billion. During the same quarter in the previous year, the business earned $9.86 EPS. McKesson’s revenue was up 7.5% compared to the same quarter last year. As a group, research analysts forecast that McKesson Corporation will post 44.71 EPS for the current fiscal year.

McKesson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, January 4th. Stockholders of record on Tuesday, December 1st will be given a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Tuesday, December 1st. McKesson’s dividend payout ratio (DPR) is currently 9.67%.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. Citigroup lifted their price objective on McKesson from $945.00 to $1,000.00 and gave the stock a “buy” rating in a report on Friday, July 24th. Weiss Ratings upgraded McKesson from a “buy (b-)” rating to a “buy (b)” rating in a research report on Friday, September 4th. Evercore reaffirmed an “outperform” rating and issued a $950.00 price target (down from $1,000.00) on shares of McKesson in a research note on Thursday, August 6th. Wall Street Zen upgraded McKesson from a “hold” rating to a “buy” rating in a research report on Saturday, October 17th. Finally, Leerink Partners boosted their price objective on McKesson from $1,070.00 to $1,200.00 and gave the company an “outperform” rating in a research report on Thursday. Fifteen equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, McKesson currently has an average rating of “Moderate Buy” and an average target price of $1,023.24.

About McKesson

McKesson Corporation is a healthcare services and information technology company that distributes pharmaceuticals and medical products to pharmacies, hospitals, health systems, physicians and other healthcare providers. The company also provides technology, data and business solutions designed to support prescription management, pharmacy operations and patient care.

McKesson’s principal activities include pharmaceutical distribution, medical-surgical supply distribution, specialty pharmaceutical services and oncology care support.